Seismic Hopes To Shake Up Immunology With New Financing
Financing Snapshot: The AI/ML-focused company raised $101m in a series A round and plans to use the funding to develop immunoglobulin- and cell-mediated autoimmune disorder drugs.
You may also be interested in...
Building on an alliance dating back to 2016, Exscientia and Sanofi will use artificial intelligence and insights gleaned from patient tissue samples to seek out 15 novel therapies.
The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.